Search

News 10 Warning Signs of Primary and Secondary Immunodeficiencies

The Jeffrey Modell Foundation (JMF) proposed 10 warning signs of primary immunodeficiencies (PID). The study presented below examined whether they are applicable to secondary immunodeficiencies (SID) and whether there are any additional signs that could help in diagnosing SID.

Source: Primary and Secondary Immunodeficiencies 1. 12. 2023

News Limosilactobacillus reuteri as a supplement for improving periodontal health when oral hygiene is compromised

The effect of probiotics on periodontal health was investigated in a German study conducted on a group of sailors during their service at sea. Among the most common causes of the overgrowth of virulent pro-inflammatory microorganisms in the oral microbiota is impaired oral hygiene, which is significantly hindered in the conditions of a naval mission.

Source: GI, colic and microbiome 6. 9. 2022

News At the Crossroads: 5 Options for Alzheimer's Disease Pharmacotherapy

Currently, we have 5 basic options for the pharmacotherapy of Alzheimer's disease. Is memantine, one of the three cholinesterase inhibitors, or combination therapy the most effective? A review article by Japanese and American authors evaluates the literature on the safety and efficacy of cognitive treatments for Alzheimer's disease.

Source: Viral infections 9. 2. 2023

News Trifluridine/Tipiracil in the 3rd Line Treatment of mCRC −⁠ Case Study

The following case study describes the treatment of a patient with metastatic colorectal cancer (mCRC) and the benefits of trifluridine/tipiracil within the therapeutic algorithm.

Source: Treatment of Gastrointestinal Carcinomas 3. 2. 2021

News End of Unnecessary Biopsies? Prostate Health Index (PHI) in Detecting Aggressive Carcinoma

The Prostate Health Index (PHI) combines the results of three blood-derived parameters: total PSA (tPSA), free PSA (fPSA), and [-2]proPSA (p2PSA) into a single numerical score: PHI = (p2PSA / fPSA × √tPSA). It is a marker used to differentiate patients indicated for prostate biopsy, enabling prediction of cancer aggressiveness and helping to choose the optimal course of action for a particular patient. Its benefit in distinguishing aggressive prostate cancer from indolent tumors or benign lesions was already proven in 2015.

Source: Prostate Health Index 2. 2. 2020

News Early Intervention in the Early Phase of Psychosis

A meta-analysis of 10 randomized studies examined whether early intervention in the initial phase of psychosis in patients with schizophrenia is associated with better outcomes than usual care.

Source: Modern Treatment of Schizophrenia 27. 10. 2021

News Innovation in Wound Healing: Zetuvit Plus Silicone Border for Optimal Wound Exudate Management

Excessive wound exudate can lead to delayed healing, skin damage around the wound, or leakage under the chosen dressing. Zetuvit Plus Silicone Border dressing with high absorbent and retention capacity offers confidence in treating both chronic and acute wounds and high comfort for the patient.

Source: Wound Healing 26. 9. 2023

News Efficacy of Sublingual Immunotherapy in Patients with Atopic Dermatitis Sensitized to Dust Mite Allergens

In patients with atopic dermatitis (AD), sensitization to house dust mite allergens is common. According to studies, subcutaneous immunotherapy (SCIT) represents an effective adjunct therapy. The clinical study presented below is one of the few that explored the efficacy of sublingual immunotherapy (SLIT) containing Dermatophagoides pteronyssinus extract.

Source: Dust Mite Allergy 11. 3. 2022

News Benefit of Oral Semaglutide for Patients with Type 2 Diabetes in the General Practitioner's Office

Oral semaglutide is a modern antidiabetic suitable within primary care for people with type 2 diabetes, primarily due to its comprehensive action that includes not only reducing blood glucose and body weight but also a number of other favorable non-glycemic effects.

Source: Modern Treatment of Diabetes with GLP-1 Analogues 22. 5. 2024

News Irritable Bowel Syndrome and Non-specific Inflammatory Bowel Diseases Are Not Evolutionarily Related Diseases

The authors of the presented work attempted to compare the geographical distribution of irritable bowel syndrome and non-specific inflammatory bowel diseases and other factors related to these two diseases to reveal their potential evolutionary connection.

Source: Irritable Bowel Syndrome 19. 6. 2021

News When You Say Amyloid…

The term 'amyloid' was first used by the German doctor Rudolf Virchow in the mid-19th century. He described it as a pathological substance which he originally thought was starch. Although it was quickly discovered that it was a substance of protein nature, the reference to starch (from the Greek amylon) remained in the name.

Source: Amyloidosis 12. 12. 2022

Články časopisu Telemedicine and inflammatory bowel disease –⁠ results of the IBD Assistant pilot project

Author of the article: Malíčková K., Pešinová V., Bortlík M., Ďuricová D., Machková N., Hrubá V., Lukáš M. Jr., Mitrová K., Vašátko M., Kostrejová M., Kolář M., Lukáš M. Source: Gastroenterologie a hepatologie | 1/2020 25. 2. 2020

News Three times on the topic of therapeutic cannabis usage possibilities –⁠ case studies from Czech practice

The following case studies from real Czech practice describe three cases of patients with various diagnoses, indicated for cannabis extract administration. In the first case, there was significant pain relief in an elderly patient with vertebrogenic pain syndrome. The second case study outlines the possibilities of using cannabis extract in the treatment of neuropathic pain in a polymorbid elderly patient. The final contribution describes the effect of this preparation in palliative therapy of an oncological patient.

Source: Medical Cannabis 27. 9. 2023

News Is Dupilumab Effective in AD Therapy for Patients for Whom Cyclosporine A Fails or Cannot Be Given?

Severe forms of atopic dermatitis (AD) may require systemic therapy. However, the immunosuppressant cyclosporine A does not have sufficient efficacy in some patients with AD or is contraindicated for them. Therefore, the phase III clinical trial LIBERTY AD CAFÉ evaluated the efficacy of dupilumab in these patients.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 3. 3. 2022

News ICIS Report: Potential of TPO-RA as Early Immunomodulatory Treatment of Immune Thrombocytopenia

The report from the meeting of the Intercontinental Cooperative ITP Study Group (ICIS) in 2022 in Lenzerheide, Switzerland, published late last year in the British Journal of Haematology, discusses the potential of early treatment of immune thrombocytopenia with thrombopoietin receptor agonists (TPO-RA) in achieving a disease remission sustainable without further therapy.

Source: Immune Thrombocytopenia 24. 1. 2024